ACADIA PHARMACEUTICALS INC. Accrued Liabilities, Current
ACADIA PHARMACEUTICALS INC. (ACAD) had Accrued Liabilities, Current of $316.87 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $316.87M.
- 2026-03-31: Accrued Liabilities, Current $293.28M.
- 2025-12-31: Accrued Liabilities, Current $266.21M.
- 2025-09-30: Accrued Liabilities, Current $334.84M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $316.87M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $293.28M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $266.21M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $334.84M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $309.93M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $284.44M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $378.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $324.86M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $317.97M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $311.26M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $236.71M 10-K · filed 2025-02-27 |
| 2023-09-30 | $197.29M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $169.13M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $206.88M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $112.88M 10-K · filed 2024-02-28 |
| 2022-09-30 | $106.56M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $105.83M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $108.83M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $89.19M 10-K · filed 2023-02-28 |
| 2021-09-30 | $80.50M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $86.26M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $100.52M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $97.47M 10-K · filed 2022-03-01 |
| 2020-09-30 | $88.39M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $79.96M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $93.12M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $67.60M 10-K · filed 2021-02-25 |
| 2019-09-30 | $64.30M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $59.16M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $71.71M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $56.40M 10-K · filed 2020-02-27 |
| 2018-09-30 | $38.85M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $45.88M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $43.09M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $40.24M 10-K · filed 2019-02-27 |
| 2017-09-30 | $33.18M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $37.33M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $38.97M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $36.03M 10-K · filed 2018-02-27 |
| 2016-09-30 | $34.45M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $27.48M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $19.82M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $20.23M 10-K · filed 2017-02-28 |
| 2015-09-30 | $15.53M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $16.46M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $14.13M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $13.82M 10-K · filed 2016-02-29 |
| 2014-09-30 | $10.13M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $8.21M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $6.43M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $6.55M 10-K · filed 2015-02-26 |
| 2013-09-30 | $6.67M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $6.49M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $4.16M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $4.14M 10-K · filed 2014-02-27 |
| 2012-09-30 | $4.69M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $5.22M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $4.69M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $3.50M 10-K · filed 2013-03-12 |
| 2011-09-30 | $4.40M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $4.01M 10-Q · filed 2011-08-10 |
| 2010-12-31 | $3.22M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |